Think of Leqvio as a Niche Med for Lowering LDL

February 2022

Rx Leqvio (inclisiran) will be the first “small interfering RNA” therapy for lowering cholesterol.

This injectable works at a different step in the same pathway as the PCSK9 inhibitors, Praluent (alirocumab) and Repatha (evolocumab).

Leqvio prevents formation of the PCSK9 protein...Praluent and Repatha prevent PCSK9 binding. All of them increase LDL receptors in the liver and clearing of LDL cholesterol from the blood.


Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote